Key result
Combining beta-blockers and ACE inhibitors reduces cardiovascular morbidity and mortality in high-risk patients.
Why the study?
Hypertensive patients with cardiovascular disease or comorbidities often require dual combination therapy, highlighting the need to summarize evidence for combining beta-blockers and ACE inhibitors.
Combination therapy with beta-blockers and ACE inhibitors is beneficial for cardioprotection and reducing cardiovascular morbidity and mortality in high-risk patients with hypertension and cardiovascular diseases.
May support dual therapy in high-risk patients; leaves open randomized confirmation of benefits.
Patients with hypertension, especially when complicated by cardiovascular disease (CVD) and/or comorbidities, require long-term treatment with a combination of antihypertensive drugs, which often gives rise to complex drug regimens. Dual-agent combination antihypertensive therapy is recommended in most patients with hypertension, and where available, a fixed-dose single-pill combination (SPC) is recommended. The combination of antihypertensive drugs should take into account the patient's overall CVD risk profile (other CVD risk factors and diagnoses). The combination of a beta-blocker and angiotensin-converting enzyme inhibitor (ACEi) acts on two neuroendocrine systems implicated in the pathophysiology of hypertension and multiple CVD: beta-blockers on the sympathetic nervous system and ACEis on the renin-angiotensin system (RAS). A large body of solid evidence states that, in addition to their antihypertensive effects, both beta-blockers and ACEis provide cardioprotection and guarantee reductions in CV morbidity and mortality in patients with coronary artery disease (CAD), atrial fibrillation, and heart failure. For these reasons, such a combination might be beneficial for many patients. This review summarizes the evidence supporting the use of beta-blockers and ACEis, as well as the rationale behind their combined administration, particularly in patients with a high risk of CVD, such as those with ischemic heart disease, atrial fibrillation, or heart failure.
No takes yet. Share an insight, caveat, or question.
A Virdis (2026) conducted a review in Cardiovascular diseases (hypertension, ischemic heart disease, atrial fibrillation, heart failure). Combination therapy with beta-blockers and ACE inhibitors (Bisoprolol/Ramipril) was evaluated. Combination therapy with beta-blockers and ACE inhibitors provides cardioprotection and reduces cardiovascular morbidity and mortality in patients with high cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: